FDA Extends Review Period for AstraZeneca's Breast Cancer Drug Camizestrant
AZN sits 43% above its 52-week low of $131.03.
Summary
The US FDA has extended the review period for AstraZeneca's breast cancer drug camizestrant, requesting additional data following a non-majority vote from its advisory committee.
Key Events · Product Development and Regulatory · AZN
-
FDA PDUFA Date Extended
The US Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for camizestrant's New Drug Application (NDA).
-
Additional Data Requested
The extension is to allow for the review of additional data provided by AstraZeneca to support the application for camizestrant in 1st-line HR-positive, HER2-negative advanced breast cancer with an emergent ESR1 mutation.
-
Prior Advisory Committee Vote
In April 2026, the FDA's Oncologic Drugs Advisory Committee did not reach a majority vote in favor of camizestrant's benefit in this setting.
-
Upcoming Data Presentation
Additional analyses, including ctDNA clearance data, will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2.
Analysis · AZN · Life Sciences
The FDA's decision to extend the review period for camizestrant's New Drug Application (NDA) delays potential market entry for this breast cancer treatment. This follows a mixed advisory committee vote in April, indicating the FDA requires more data to be convinced of the drug's benefit in this specific treatment strategy. While AstraZeneca is providing additional analyses, the delay introduces uncertainty and pushes back potential revenue.
How filings like this one have moved
In the 30 days to Sep 21, 2026, 29.2% of the 1541 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AZN was trading at $187.38 on NYSE in the Life Sciences sector, with a market capitalization of approximately $290.3B. The 52-week trading range was $131.03 to $212.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.